Unternehmensübersicht
Agilon Health, Inc. operates within the healthcare sector, specifically focusing on the Medical Care Facilities industry, where it delivers primary care services to senior populations across the United States. The company utilizes a subscription-based business model that manages the total healthcare needs of its patients through a per-member per-month fee structure, distinguishing its operational approach from traditional fee-for-service providers. With a market capitalization of $306.71M and an annual revenue of $5.93B over the trailing twelve months, Agilon Health employs a workforce of 856 individuals to execute its platform strategy. These valuation figures indicate a mid-sized enterprise operating with significant top-line volume, though the market capitalization relative to revenue suggests a valuation that does not yet fully reflect the magnitude of its reported sales, pointing to potential market skepticism regarding profitability or a focus on long-term structural value over current earnings multiples.
Finanzielle Gesundheit
The financial performance for the trailing twelve months demonstrates a revenue of $5.93B, which is contrasted by a net income of -$405,347,008 and an EBITDA of -$406,182,016, revealing a substantial gap between gross sales and bottom-line earnings. This disparity indicates a cost structure where operating expenses and other deductions significantly erode the bottom line, resulting in a loss that is nearly identical to the EBITDA figure, implying high overhead or significant non-operating costs impacting the final net result. The company generated a free cash flow of -$81,226,128, which signifies a current lack of financial flexibility to fund operations solely through internal cash generation without relying on external capital markets or asset monetization. Margin analysis shows a gross margin of -2.7%, an operating margin of -10.0%, and a profit margin of -6.6%, all of which indicate that the company is currently operating at a loss at every level of its income statement, from the cost of goods sold to the final net profit. On the balance sheet, Agilon Health holds $285.14M in cash against $36.81M in debt, supported by a debt-to-equity ratio of 29.05, suggesting a highly conservative liquidity position with substantial cash reserves relative to its obligations. The current ratio stands at 1.02, indicating that the company's current assets slightly exceed its current liabilities, providing a minimal but positive buffer for short-term liquidity needs. Furthermore, the return on equity is -135.6% and the return on assets is -17.5%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and the asset base utilized to run the business.
Bewertungsanalyse
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is reported at -4.33, implying that the market anticipates continued losses or a significant turnaround in earnings trajectory. The price-to-book ratio is 2.42, indicating that the market values the company at a significant premium over its tangible book value, which is unusual for a loss-making entity and suggests high growth expectations or intangible asset valuations not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.05 and an EV/EBITDA of -0.14 further illustrate the disconnect between current stock price and operational reality, suggesting the market is pricing in a future recovery rather than current cash flows. The stock trades with a 52-week high of $152.00 and a 52-week low of $7.48; given the historical volatility, the current trading price sits significantly below the 52-week high, reflecting a substantial retracement from previous peaks. The beta of 0.33 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the market index in either direction, which offers a distinct risk profile compared to typical healthcare equities.
Growth & Income
Revenue growth year-over-year is recorded at 3.1%, while earnings growth is listed as N/A due to the absence of positive earnings, highlighting a scenario where top-line expansion is occurring without corresponding bottom-line improvement. The gap between the 3.1% revenue growth and the lack of earnings growth implies that the company is prioritizing market share expansion or platform deployment over immediate profitability, a common strategy in the early stages of scaling a healthcare technology platform. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, choosing instead to retain earnings and deploy capital into growth initiatives rather than paying dividends. The overall growth and income profile characterizes Agilon Health as a high-growth, loss-making entity that reinvests all available capital back into the business to fuel future expansion rather than providing current income to investors.